CTA
NVIV

Colonial Trust Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Colonial Trust Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$1 – 1094
2023
Q4 		$1 Hold
2
– – ﹤0.01% 910
2023
Q3 		$2 Hold
2
– – ﹤0.01% 915
2023
Q2 		$3 Hold
2
– – ﹤0.01% 913
2023
Q1 		$2 Hold
2
– – ﹤0.01% 905
2022
Q4 		$5 Buy
+2
New +$5 ﹤0.01% 912

Other funds holding NVIV

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VL
Vima LLC Troy, Michigan $103M AUM

Colonial Trust Advisors's NVIV Position: Q1 2024 in Review

Colonial Trust Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 2 shares — an estimated $1 sold.

Colonial Trust Advisors first reported a position in NVIV in Q4 2022 and held it in 5 quarters. The position peaked at $5 in Q4 2022. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.

  • Colonial Trust Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
  • Colonial Trust Advisors sold 2 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $1.
  • Colonial Trust Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q4 2022 and held it in 5 quarters.
  • Colonial Trust Advisors's InVivo Therapeutics Holdings Corp position peaked at $5 in Q4 2022.
  • 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.

Based on Colonial Trust Advisors's 13F filing for Q1 2024, filed 14 May 2024.